How should candiduria be treated in a patient who cannot receive azole antifungals?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Candiduria in Patients with Azole Allergy

For patients allergic to azole antifungals, amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days (with or without oral flucytosine 25 mg/kg four times daily) is the treatment of choice for symptomatic Candida urinary tract infections. 1

Initial Assessment: Determine if Treatment is Actually Needed

Before initiating any antifungal therapy, recognize that most candiduria represents benign colonization and does not require treatment—even in patients who cannot receive azoles. 1

Non-Pharmacologic Management (First-Line for All Patients)

  • Remove any indwelling urinary catheter immediately—this single intervention clears candiduria in approximately 50% of cases without any antifungal drugs. 1, 2
  • Discontinue unnecessary broad-spectrum antibiotics, as these are major drivers of candiduria. 1
  • Eliminate urinary tract obstruction and remove or replace nephrostomy tubes or ureteral stents when present. 1

High-Risk Populations Requiring Treatment Despite Lack of Symptoms

Even without azole options, you must treat asymptomatic candiduria in: 1

  • Neutropenic patients with persistent unexplained fever and candiduria (risk of disseminated candidiasis)
  • Very low-birth-weight neonates (<1500 g)
  • Patients undergoing urologic procedures or instrumentation within several days
  • Patients with urinary tract obstruction that cannot be promptly relieved

Treatment Regimens for Symptomatic Infections

Symptomatic Candida Cystitis (Lower UTI)

  • Amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days is the primary alternative when fluconazole cannot be used. 1, 2
  • Oral flucytosine 25 mg/kg four times daily for 7–10 days can be added to amphotericin B or used as monotherapy (weaker recommendation for monotherapy). 1
  • For refractory cystitis, bladder irrigation with amphotericin B deoxycholate 50 mg/L sterile water daily for 5 days may be employed, though relapse rates are high (80–90%). 1, 3

Symptomatic Candida Pyelonephritis (Upper UTI)

  • Amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily with or without oral flucytosine 25 mg/kg four times daily for 14 days total is recommended. 4
  • If percutaneous access to the renal collecting system is available, adjunctive irrigation with amphotericin B deoxycholate 25–50 mg diluted in 200–500 mL sterile water can be added to systemic therapy. 1, 4

Pre-Procedure Prophylaxis

  • For patients undergoing urologic procedures who cannot receive azoles, use amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for several days before and after the procedure. 1, 5

Species-Specific Considerations

  • Candida glabrata is often fluconazole-resistant, making amphotericin B the logical choice regardless of allergy status. 1, 5
  • Candida krusei is intrinsically fluconazole-resistant; amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days is the treatment of choice. 1

Treatment Duration

  • Cystitis: 1–7 days of IV amphotericin B (or 7–10 days of oral flucytosine) 1
  • Pyelonephritis: 14 days total 4
  • Continue therapy until symptoms resolve and urine cultures no longer yield Candida species. 4

Critical Pitfalls to Avoid

  • Do not use lipid formulations of amphotericin B for Candida urinary tract infections—they do not achieve adequate urinary concentrations and treatment failures are well-documented. 4, 6
  • Do not use echinocandins (caspofungin, micafungin, anidulafungin) for urinary Candida infections—they achieve inadequate urine concentrations and are ineffective for lower tract infections. 1, 7, 6 While one retrospective study showed some success with micafungin 8, guideline recommendations explicitly advise against echinocandins due to poor urinary penetration. 1
  • Do not use newer azoles (voriconazole, posaconazole) as alternatives—they also fail to achieve sufficient urine concentrations. 1, 7
  • For severely immunocompromised patients with fever and candiduria, treat as disseminated candidiasis with an echinocandin systemically (not for the urinary infection itself), as this may represent candidemia rather than isolated UTI. 4

Complicated Infections Requiring Surgical Intervention

  • Fungal balls (bezoars) or obstructive uropathy mandate surgical or endoscopic removal plus systemic antifungal therapy—antifungal agents alone will fail without drainage. 1, 5

References

Guideline

Treatment of Asymptomatic Candiduria

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Candida urinary tract infections in adults.

World journal of urology, 2020

Guideline

Candida Pyelonephritis Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Male with Yeast in Urine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Candida urinary tract infections--treatment.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011

Research

Candida urinary tract infections: treatment options.

Expert review of anti-infective therapy, 2007

Related Questions

What is the recommended treatment for a 55-year-old female with candiduria (fungal infection of the urine)?
What is the recommended treatment for a urinary tract infection (UTI) with 50,000-99,000 Colony-Forming Units per milliliter (CFU/mL) of Candida lusitaniae?
What is the diagnosis for an 18-year-old female presenting with dysuria (painful urination), leukocyturia (leukocytes in urine) indicated by a dipstick urinalysis showing a significant number of leukocytes, and a urine culture revealing candiduria (presence of Candida in urine) with a colony-forming unit (CFU) count of 10,000-49,000 CFU of Candida albicans?
What is the next step for an 85-year-old febrile man with a chronic suprapubic (urinary catheter inserted through the lower abdomen) tube and persistent candiduria (fungal infection of the urine) after suprapubic tube change?
What is the treatment for a symptomatic yeast infection in the urine, specifically for a patient with yeast on urine culture?
What are the differential diagnoses for widespread body cramps?
What empiric antibiotic regimen should be given to high‑risk patients (e.g., older age, significant comorbidities, recent antibiotic use, immunosuppression, or healthcare‑associated exposure) with pneumonia?
What is serum osmolarity?
In a patient with an acute coronary syndrome (non‑ST‑segment elevation myocardial infarction or ST‑segment elevation myocardial infarction) who has not yet had a lipid profile, should I start a high‑intensity statin now?
Which patients with permanent vitamin B12 malabsorption—such as autoimmune pernicious anemia (intrinsic‑factor deficiency), total or partial gastrectomy, bariatric procedures that bypass the duodenum and proximal jejunum (e.g., Roux‑en‑Y gastric bypass), surgical resection of the terminal ileum (including extensive Crohn’s disease surgery), inherited disorders impairing cobalamin transport or metabolism (transcobalamin II deficiency, hereditary cobalamin metabolic defects, methylmalonic acidemia), elderly individuals with irreversible atrophic gastritis, or those on chronic high‑dose proton‑pump inhibitors (PPIs) or metformin when the drugs cannot be stopped—require lifelong vitamin B12 supplementation?
Should a patient with acute coronary syndrome and normal LDL‑cholesterol and total cholesterol still be started on high‑intensity statin therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.